| Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ... JAMA neurology 77 (2), 184-191, 2020 | 433 | 2020 |
| Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ... Neurology 87 (20), 2074-2081, 2016 | 375 | 2016 |
| Rituximab versus fingolimod after natalizumab in multiple sclerosis patients P Alping, T Frisell, L Novakova, P Islam‐Jakobsson, J Salzer, A Björck, ... Annals of neurology 79 (6), 950-958, 2016 | 240 | 2016 |
| Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients P Alping, J Askling, J Burman, K Fink, A Fogdell‐Hahn, M Gunnarsson, ... Annals of neurology 87 (5), 688-699, 2020 | 101 | 2020 |
| Validation of the Swedish multiple sclerosis register: further improving a resource for pharmacoepidemiologic evaluations P Alping, F Piehl, A Langer-Gould, T Frisell, COMBAT-MS Study Group Epidemiology 30 (2), 230-233, 2019 | 52 | 2019 |
| Safety of alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis P Alping, J Burman, J Lycke, T Frisell, F Piehl Neurology 96 (11), e1574-e1584, 2021 | 19 | 2021 |
| Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. P Alping, F Piehl, T Frisell Multiple Sclerosis Journal 24, 36-36, 2018 | 6 | 2018 |
| Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study K Fink, A Gorczyca, P Alping, S Englund, S Farmand, AM Langer-Gould, ... Multiple Sclerosis Journal 29 (6), 731-740, 2023 | 5 | 2023 |
| Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies (vol 77, pg 184, 2020) G Luna, P Alping, J Burman JAMA NEUROLOGY 78 (11), 1413-1413, 2021 | 4 | 2021 |
| Safety outcomes after treatment with alemtuzumab or autologous hematopoietic stem cell transplantation in multiple sclerosis patients P Alping, J Burman, J Lycke, T Frisell, F Piehl MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 352-353, 2020 | 2 | 2020 |
| Rituximab does not increase the risk of malignancy or breast cancer in two large US and Swedish rituximab-treated multiple sclerosis cohorts A Langer-Gould, P Alping, J Smith, B Li, F Piehl, T Frisell Multiple Sclerosis Journal 25, 570-571, 2019 | 2 | 2019 |
| Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab P Alping Basic & Clinical Pharmacology & Toxicology 133 (5), 550-564, 2023 | 1 | 2023 |
| Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis P Alping PQDT-Global, 2022 | 1 | 2022 |
| Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A … P Alping, M Neovius, F Piehl, T Frisell Annals of Neurology, 2024 | | 2024 |
| Comparative efficacy of rituximab and other first line or first escalation options on treatment persistence, relapse rates, disability and serum neurofilament levels in a … F Trogu, CS Cucuzza, M Armiento, P Benkert, AM Maceski, J Kuhle, ... MULTIPLE SCLEROSIS JOURNAL 29, 637-638, 2023 | | 2023 |
| Rituximab treatment prior to pregnancy in women with multiple sclerosis-perinatal outcomes in Swedish cohort A Gorczyca, P Alping, T Frisell, N Razaz, F Piehl, K Fink MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 634-635, 2021 | | 2021 |
| Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, J Hillert, ... Multiple Sclerosis Journal 27 (Suppl. 2), 21-22, 2021 | | 2021 |
| Disease-modifying therapies for multiple sclerosis in association with pregnancy: a Swedish nation-wide cohort study A Gorczyca, P Alping, T Frisell, F Piehl, A Langer-Gould, K Fink MULTIPLE SCLEROSIS JOURNAL 24, 146-147, 2018 | | 2018 |
| Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location P Alping, J Burman, K Fink, M Gunnarsson, J Lycke, P Nilsson, J Salzer, ... Multiple Sclerosis Journal 23, 714-714, 2017 | | 2017 |
| Rituximab in multiple sclerosis; data from the swedish MS registry. P Alping, A Svenningsson, J Salzer, J Burman, C Dahle, K Fink, J Hillert, ... Multiple Sclerosis Journal 22 (suppl. 3), 49-49, 2016 | | 2016 |
Fredrik PiehlProfessor of neurology, Karolinska InstitutetVerified email at ki.se
